AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov. 7, 2022...

Click to view original post